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Mammalsde a brief reminder of epigenetic phenomena in general, and DNA methylation in
particular. We will then underline the characteristics of the in vivo organization of the genome that limit the
applicability of in vitro results. We will use several examples to point out the connections between DNA
methylation and nuclear architecture. Finally, we will outline some of the hopes and challenges for future
research in the ﬁeld. The study of DNA methylation, its effectors, and its roles, illustrates the
complementarity of in vitro approaches and cell biology.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
1.1. DNA methylation is an essential epigenetic mark that controls
gene expression
DNA methylation is an archetypal epigenetic mark [1,2]. It is borne
by the genetic material but does not inﬂuence its sequence. It can
regulate genomic activities, and can be maintained through mitosis
and meiosis.
DNA methylation is essential in mammals: its loss leads to growth
arrest or apoptosis in normal cells [3] as well as in cancer lines [4]. The
presence of DNA methylation is absolutely required for embryonic
development in mouse [5,6]. The key role of DNA methylation is to
control gene expression, and methylated sequences undergo tran-
scriptional repression [7].
Here we will review recent ﬁndings and concepts on the control of
gene expression by DNA methylation, with an emphasis on cell
biological aspects and a restriction to mammalian cells. We will ﬁrst
set the background with some reminders about the actors, the
effectors, and the targets of DNA methylation.
2. The proteins that set up and interpret DNA methylation
The DNA of mammals can be methylated on cytosines within the
CpG dinucleotides (Fig. 1). The added methyl groups protrude in the
major groove of DNA. When the DNA is symmetrically methylated,
bothmethyls face the same direction and are close to one another. The
addition of methyl groups changes the biophysical characteristics ofl rights reserved.the DNA and has two effects: it inhibits the recognition of DNA by
some proteins and permits the binding of others [7].
The modiﬁcation is brought about by enzymes called DNA
methyltransferases (DNMTs). There are three such enzymes in
mammals: DNMT1, DNMT3a, and DNMT3b (Table 1). DNMT3L is
structurally related, but is catalytically inactive and serves as a
cofactor for DNMT3a and DNMT3b [8]. The protein DNMT2 also has
sequence similarity to these enzymes, but its function is quite
different [9]; it will not be discussed further here. Extensive
enzymology studies have yielded important insight into the function
of these enzymes [10]. Notably, it was found that DNMT1 has
preferential activity for hemi-methylated DNA over unmethylated
DNA. It seems likely that, most of the time, DNMT3a and DNMT3b,
aided by DNMT3L, set up the new imprints on previously naked DNA.
For this they are called “de novo” methyltransferases. After DNA
replication, methylated DNA becomes hemimethylated, and DNMT1
would be themain player inmaking it fullymethylated again. It is thus
called the “maintenance” enzyme (Table 1). This slightly over-
simpliﬁed picture will sufﬁce for our purpose here, but excellent
detailed reviews are available to ﬁll in the details [8,10].
The methyl mark is translated into transcriptional repression by
the action of proteins that recognize methylated DNA and inhibit gene
expression by creating a repressive chromatin structure [7]. Three
families of proteins speciﬁcally recognize methylated DNA (Table 1)
[11,12]. The ﬁrst family contains MBD1, MBD2, MBD4, and MeCP2;
these proteins share a related DNA binding domain called Methyl-
binding Domain (MBD) [7]. The second family contains the Zinc-ﬁnger
proteins Kaiso, ZBTB4, and ZBTB38 [13,14]. These proteins are
bifunctional: they bind methylated DNA, but also some non-
methylated consensus sequences. Finally, the third family comprises
UHRF1 and UHRF2 (also known as ICBP90 and NIRF), which bind
Fig.1. Themethylation of cytosines. (A) The chemical nature of DNAmethylation. Sketch
of a cytosine and its modiﬁed counterpart. (B) The methyl groups on modiﬁed cytosines
are accessible in the major groove. The two strands of the DNA helix are colored blue
and purple, and the methyl groups are highlighted in red. Two views of the same DNA
are shown, they differ by a 90° rotation.
Table 1
The proteins involved in setting up and interpreting the methylation mark
De novo Maintenance Cofactor
DNMT3a DNMT1 DNMT3L
DNMT3b
MBD Zinc ﬁnger SRA
MeCP2 Kaiso UHRF1
MBD1 ZBTB4 UHRF2
MBD2 ZBTB38
MBD4
Top panel: the enzymes that methylate DNA in mammals.
Bottom panel: the three families of proteins that bind methylated DNA in mammals.
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domain.
An important question, discussed at length in an excellent recent
review [11] is that of the redundancy between methyl-binding
proteins. Their degree of sequence speciﬁcity is poorly characterized,
and it is unclear whether they can all bind the same target loci, or
whether they have distinct targets. Even if the proteins do share some
targets, they could be functionally different for other reasons. For
instance, they could have different DNA-binding afﬁnities. Also, the
different proteins could be expressed at different times or places.
Finally they could have different protein or nucleotide interactors that
could possibly recruit them to different compartments of the nucleus.
3. The targets of DNA methylation differ in normal and
cancer cells
In normal cells, three main types of targets are repressed by DNA
methylation (Fig. 2). First: parentally imprinted genes, i.e. genes that
are expressed differentially from the maternal and the paternalchromosome. They are key regulators of embryonic development and
adult life [15]. In most cases the inactive allele is marked by DNA
methylation, and monoallelic expression is lost in the absence of
methylation [16]. As an aside, recent data indicates that many genes
may be expressed monoallelicaly in somatic cells, but it is yet unclear
if this depends at all on DNA methylation [17]. Second: the
transposons and other repeated sequences that constitute a large
fraction of the mammalian genome [18]. Third: a number of genes are
methylated in a tissue-speciﬁc manner [19]. An interesting subset of
those are the Cancer/Testis (C/T) antigens, which are unmethylated
and expressed in the testis, and methylated and repressed in all other
tissues [20].
DNA methylation is deregulated in cancer (Fig. 2). Tumor cells
often have an abnormal pattern of DNA methylation where some
tumor suppressor genes are methylated and inactive [21]. Conversely,
some normally methylated sequences, such as repeated DNA,
imprinted genes, and C/T antigens, can become demethylated
(Fig. 2). Abnormal DNA methylation is an early causal event during
cellular transformation [22]. Demethylating agents can re-establish
the expression of silenced tumor suppressor genes and have been
approved for clinical use against some leukemias [23].
4. In vitro experiments do not reproduce some properties of
the nucleus
In vitrowork has been crucial in working out different elements of
gene regulation by DNA methylation. It has yielded insight into the
mechanisms of DNA methylation, the binding properties of methyl-
binding proteins, and the way these factors regulate gene expression.
However we should keep in mind that the inside of the nucleus
differs from a test tube in several important ways [24]. We will
mention three. First, the nuclear environment is densely packed with
macromolecules. The protein concentration in some compartments is
estimated at 500 mg/ml, and this macromolecular crowding has some
kinetic and thermodynamic effects that are usually not taken into
account in vitro. Crowding is a serious hindrance to diffusion-driven
reactions, and kinetic constants measured in vitro almost always
neglect this factor. This barrier to diffusion may be a reason why
protein recruitment is such a frequently recurring theme.We illustrate
this idea with the example of DNMT1 in section 7.
A second key issue is that nuclear proteins are not homogeneously
distributed; many proteins are found in nuclear bodies as the result of
homo- and heterotypic interactions [25]. This can have either positive
or negative consequences on their activity. In some cases, such as
transcription factories, the nuclear bodies are sites of concentration of
active proteins. In other cases, the nuclear bodies are storage sites
from which the proteins have to be released to reach their target. A
signiﬁcant consequence is that the activity of a protein can be
regulated by directing it into or out of a given area of the nucleus. This
is an interesting extension of the regulation of protein by nucleo-
cytoplasmic shuttling.
Fig. 2. The loci that undergo DNAmethylation in mammals. At least three different types of loci can be methylated in normal cells (left half of the ﬁgure). Tumor suppressor genes, as
well as the vast majority of genes with a CpG island promoter, are not methylated. In tumor cells (right half), the repeated sequences become demethylated, the imprinted genes
become aberrantly demethylated (or methylated on both alleles, a situation not represented here). Some genes which were unmethylated can become methylated and
transcriptionally silenced, and this is a frequent cause for the inactivation of tumor suppressor genes. Finally some genes that were methylated lose the mark, like the Cancer/Testis
(C/T) antigens.
2169E. Prokhortchouk, P.-A. Defossez / Biochimica et Biophysica Acta 1783 (2008) 2167–2173Thirdly, the genome isnot arrangedhomogeneouslyandnot all genes
are equally accessible to protein regulators [25]. Chromosomes occupy
given territories within the nuclear space. They have an interior and a
surface, augmented by extruded loops and channel-like invaginations.Fig. 3. Different parameters regulate DNA–protein interactions in vitro and in vivo. (A) In vitro
and binding afﬁnity. (B) In the nucleus of a cell, the situation is much more complex. The DN
envelope or the nucleolus. The DNA locus is part of a chromosome and may be more or lesMany of these features are dynamic. The proteinaceous nuclear
bodies are stable entities but the proteins that constitute them are in
ﬂux. The bodies themselves move about in the nucleus, and this may
be a mechanism for scanning the genome. The chromosomes, the interaction involves only two actors, and is determined only by their concentration
A-binding protein may interact with nuclear bodies or landmarks, such as the nuclear
s accessible to the protein.
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much inferior to that of nuclear bodies [25]. Smaller-scale movements
such as the extrusion of a chromatin loop may have more functional
signiﬁcance.
The facts presented in this section bring us to an important
conclusion (Fig. 3). Gene regulation depends on protein–DNA
interactions. These can be easily modeled in vitro, where the only
relevant parameters are the concentrations of the interactors and the
binding constants. Yet the situation in living cells is considerably more
complex: the organization of the nucleus is such that large scale
interactions must also be taken into account. An added difﬁculty is
their dynamic nature, the investigation of which demands appropriate
technical approaches, as we will discuss later.
5. Kaiso: an example of regulation by nucleo-cytoplasmic
shuttling?
The nucleo/cytoplasmic distribution of Kaiso is variable, and
responds to intracellular signals. Indeed the activation of the Wnt
pathway correlates with a movement of Kaiso out of the nucleus and
into the cytoplasm [26]. The possibility that the Wnt pathway could,
via its action on Kaiso, regulate the expression of methylated genes is
tantalizing but has not yet been substantiated. For instance, it is not
yet known whether the pool of Kaiso that shuttles in and out of the
nucleus is the pool that is devoted to binding methylated DNA. It is
possible that the methyl-binding population is immobile, whereas the
fraction that binds unmethylated DNA is mobile. The generation of
separation-of-function mutants of Kaiso, that could bind one type of
target but not the other, would be useful to answer this question.
Kaiso knock-out mice display no obvious phenotype, nor reactiva-
tion of Kaiso target genes [27]. This suggests that other proteins have
overlapping functions; ZBTB4 and/or ZBTB38 are the most likely
candidates. This possible functional overlap suggests that these two
proteins may be regulated in a similar fashion, but this has not yet
been reported.
In contrast to Kaiso, the MBD proteins seem to be constitutively
nuclear [11]. Details regarding their localization at higher resolution
are scarce, however. Sumoylation, which is known to regulateFig. 4. Localization of the methyl-binding protein ZBTB4 in mouse cells. (A) Mouse 3T3 ﬁbrob
ﬂuorescent protein GFP. Top panel: the nucleus, stained with DAPI. Bottom panel: the gre
scheme. The DAPI-dense foci, known as chromocenters, correspond to the clustering of pe
methylated (red circles).subnuclear distribution in some proteins, occurs on MBD1 but has
no effect on its localization [28]. In mouse cells, transfected MBD
proteins are recruited to the chromocenters, i.e. the clusters of
pericentric heterochromatin that are densely methylated. This is also
the case for ZBTB4 (Fig. 4), but care should be takenwhen interpreting
these experiments, as transfected proteins are usually overexpressed
and do not necessarily reﬂect the behavior of the endogenous
proteins. There are no chromocenters in human cells, in which the
MBDs appear to be diffuse nuclear proteins [11]. Some questions are
unresolved. Active genes tend to localize to “transcription factories”,
whereas genes repressed by the Polycomb proteins are recruited to
“Polycomb bodies” [29].What aboutmethylated genes? Amechanistic
link between Polycomb repression and DNA methylation has been
proposed [30], but methylated genes, and the MBD proteins, are not
known to colocalize with Polycomb bodies. The presence of unbound
proteins, which we will mention in the next section, may obscure the
existence of subnuclear enrichments of the different methyl-binding
proteins.
More generally, it is unclear if methylation results in gene repression
because it drags to the locus to a repressive environment, or because it
removes it from a permissive environment, or both, or neither. Having a
better idea of where the methyl-binding proteins localize in relation to
nuclear structures would help answer this question.
6. Much remains to be learnt about the dynamics of the
methyl-binding proteins
The in vivo dynamics of some heterochromatin proteins has been
well studied. Work on HP1 yielded the surprising result that, even
though heterochromatin is functionally stable, the heterochromatin
proteins themselves are in rapid ﬂux: they exchange in an out of the
chromatin domains quickly. For HP1, 50% recovery after photobleach-
ing of heterochromatic regions occurred in about 2.5 s [31]. The
knowledge of these kinetic parameters gives insight into the
mechanism by which these proteins act, and the possible means by
which they may be regulated.
In contrast, relatively little is known about the dynamics of methyl-
binding proteins.lasts were transiently transfected with an expression vector for ZBTB4 fused to the green
en ﬂuorescence signal, which colocalizes with the DAPI-dense foci. (B) Interpretative
ri-centromeric repeats (arrows) from several chromosomes. These repeats are heavily
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(Fluorescence Recovery After Photobleaching) in living mouse cells
[32]. Two populations of MeCP2 can be identiﬁed. One, localized in the
nucleoplasm, is highly dynamic with a t1/2 of 0.1 s, suggesting that
there is a pool of unbound protein. The second population is bound to
the chromocenters. There, its residence time is higher (t1/2=25 ss,
consistent with earlier reports [33]). This is much longer than the
residence time of HP1, and it may reﬂect additional interactions that
retain the protein to chromatin. The other MBDs have not been
similarly studied and, to the best of our knowledge, no information is
yet published regarding UHRF1, UHRF2, or the Zinc ﬁnger proteins
Kaiso, ZBTB4, and ZBTB38.
The results of immunoﬂuorescence experiments performed on
ﬁxed cells are available for almost all of these proteins, but they only
provide a snapshot of the protein distribution at a given time. They do
not inform us about the dynamics: the same immunoﬂuorescence
picture could actually reﬂect two very different situations. A very
dynamic situation, with rapid association and dissociation, would give
the same appearance as a very static situation in which movement is
rare. These two extreme situations impose very different character-
istics on the way the proteins can act and can be regulated.
7. The recruitment of DNMT1 for DNA replication and
transcriptional repression
In order to maintain the epigenetic information, the DNA
methylation marks have to be reproduced after each round of DNA
replication. A link between replication and the DNA methylation
machinery was found early on when it became apparent that DNMT1
interacts directly with the sliding clamp PCNA [34]. It was also foundFig. 5. Two recruitment events insure faithful DNA remethylation after replication. Left pane
red circle) become hemimethylated (red semi-circle). The DNA methyltransferase DNMT1
replication fork progresses, DNMT1 is transferred to the hemimethylated sites, and newprote
Finally, the loaded DNMT1 can track along the genome to remethylate sites that have been ig
does not depend on DNA replication (A). Instead, it involves the protein UHRF1, which has s
UHRF1 no longer interacts with the fully methylated sites re-created by DNMT1 (D).that DNMT1 colocalizes with the replication machinery in S-phase,
and this gave rise to a model in which the DNA was remethylated by
DNMT1 concurrently to its synthesis (Fig. 5, left panel). However,
kinetic studies later made it clear that the speed of DNAmethylation is
much smaller than the speed of DNA replication, which questioned
the validity of this simple model [10]. This yielded a reﬁned picture, in
which DNMT1 is assumed to be loaded onto DNA by the moving
replication fork, and then to re-methylate DNA at its own speed (Fig. 5,
right panel).
This model is probably true but incomplete. Indeed, DNMT1 can be
loaded onto chromatin outside of S-phase [35]. Moreover, the PCNA-
interacting region of DNMT1 can be removed without major
consequences for DNA remethylation [36,37]. The missing link for
DNMT1 targeting was very recently identiﬁed in two independent
papers [38,39]. The methyl-binding protein UHRF1 was shown to i)
bind hemi-methylated DNA ii) recruit DNMT1 and iii) be necessary for
the maintenance of methyl marks. It is likely that most DNMT1
molecules are brought to hemimethylated sites via UHRF1, as depicted
in Fig. 5.
It is worth stressing that, even though DNMT1 has clear afﬁnity for
and activity on hemimethylated sites in vitro, this is not sufﬁcient to
target it to these sites in vivo. The afﬁnity of the protein for its sites
may be too low in relation to their relative concentrations, or the
obstacles to diffusion may too great, or both. In any event, this is an
interesting illustration of the principle outlined in Fig. 4.
While the reproduction of marks by DNMT1 is relatively well
understood, little is known about the mechanisms by which DNMT3a
and DNMT3b establish their imprints at given loci. The enzymes have
some degree of sequence speciﬁcity towards speciﬁc arrangements of
CpGs [40], and a preference for regions lacking euchromatin marksl. A. As DNA is replicated, the sites that were previously symmetrically methylated (full
interacts with the replication protein PCNA, which slides along the DNA. B. As the
in is loaded onto PCNA. C. DNMT1 remethylates the hemimethylated site it is bound to D.
nored. Right panel. A second mechanism for targeting DNMT1 to hemimethylated sites
peciﬁc afﬁnity for hemimethylated sites (B), and which can directly recruit DNMT1 (C).
2172 E. Prokhortchouk, P.-A. Defossez / Biochimica et Biophysica Acta 1783 (2008) 2167–2173[41], but additional targeting mechanisms are likely to exist. One
aspect of the regulation may be that some regions are made accessible
to, or are protected from the enzymes by their respective localization
in the nuclear space, but this has not yet been shown.
The recruitment of DNA methyltransferases also occurs in the
context of transcriptional regulation. DNMT1 serves as a corepressor
for certain transcription factors, such as p53 [42] and Daxx [43]. The
heterochromatin protein HP1, which is a global repressor, also recruits
DNMT1 [44]. C-myc represses some of its target genes by recruiting
DNMT3a [45]. Transcriptional inhibition in all these cases results in
DNA methylation and may cause a repression that is more stable than
what is obtained by histone modiﬁcations only. Again, it is unclear if
methylation systematically causes the target locus to join a hetero-
chromatic area of the nucleus.
8. Is MeCP2 a structural component of the nucleus in
differentiated cells?
The amount of MeCP2 in cells increase as they differentiate, and it
reaches surprisingly high levels. It has been estimated that there are
on average 6×106 molecules of MeCP2 per brain cell [46]. This is close
to the estimated number of nucleosomes in the cells, which is 3×107
[47]. If MeCP2 binds only nucleosomes in heterochromatin, and if
heterochromatin is estimated to constitute one third of the genome,
then there is almost onemolecule ofMeCP2 for every heterochromatic
nucleosome. This raises the possibility that MeCP2, in addition to, or
maybe instead of, being a gene-speciﬁc transcriptional repressor,
might function as a structural component of the nucleus in neurons. In
this respect it might play a role similar to that of SATB1. This protein is
a structural component of nuclei in the lymphocytic lineages, where it
regulates the expression of many genes [48].
The lack of MeCP2 in neurons causes Rett syndrome [49].
Intriguingly, the symptoms can be reversed in mice by reintroduction
of an active copy of MeCP2 [50]. The hypothesis most frequently used
to explain the syndrome is that lack of MeCP2 leads to the
inappropriate re-expression of some methylated genes, which then
impair neuronal function. Curiously, however, only a handful of genes
have been shown to be repressed by MeCP2 in neurons in a
methylation-dependent manner, and they probably do not account
for the severe phenotype observed. As an alternative explanation,
MeCP2 has been reported to inﬂuence splicing [51]. However MeCP2
has not been observed to be a stoichiometric component of
spliceosomes, at least in cultured cells [52]. A third possibility would
be that MeCP2 indeed plays the role of a scaffold. The lack of MeCP2
might result in a structural weakening of the nuclear architecture,
and/or a global loosening of the transcriptional program of neurons.
Neither alteration could be clearly diagnosed using the methods
currently employed (microarray and differential expression). Because
mRNA splicing is intimately linked to nuclear export, structural
defects in the absence of MeCP2 could also account for the splicing
abnormalities observed. If this situationwere true, it would present an
interesting parallel to the human diseases named “laminopathies”, in
which mutations of the lamins affect the structure of the nucleus and
result in severe phenotypes [53].
The possibility that MeCP2 could be a scaffold that links nucleo-
somes is supported by some biochemical experiments [54]. It is also
consistent with the fact that MeCP2 overexpression causes chromo-
centers to cluster [55]. However, it seems to conﬂict with two other
pieces of data. First, neurons lacking MeCP2 have a morphologically
normal nucleus. This contrasts with nuclei from laminopathy patients,
which aremisshapen. Of course,morphology is a coarse readoutwhich
may not reﬂect subtle defects. A second observation is the above
mentioned fact that MeCP2 is fairly mobile in the cell [32]. MeCP2
behaving dynamically seemshard to reconcilewith the idea that itmay
be a structural component. One caveat of the in vivo studies, however,
is that they were done using ﬁbroblasts, not neurons.9. Technical challenges and advances
As for many other ﬁelds, our understanding of DNA methylation in
the context of the nucleus is critically dependent upon the tools we
have.
Live-cell imaging has yielded data which was unobtainable by the
study of ﬁxed cells. The DNMTs and MeCP2 have been well studied in
live cells, and hopefully the other methyl-binding proteins will also
be investigated by these methods. To be maximally signiﬁcant, a
study should use cells in which the ﬂuorescent proteins are
expressed at levels lower than the endogenous counterpart, so as
not to interfere with its distribution. Also, this should be done in a
physiologically relevant cell type. This can be done by stable
transfection and selection of clones, or, ideally, by fusing a ﬂuorescent
tag to the endogenous protein by homologous recombination (knock-
in). These requirements may be difﬁcult to fulﬁll, but the rewards can
be great.
Microscopy is not the only way to examine the architecture of the
nucleus. Molecular biology approaches have been very fruitful as well.
The identiﬁcation of methylated sequences has been greatly facilitated
by a variant of chromatin-immunoprecipitation called MeDIP [56].
Other techniques give insight into the possible 3D arrangement of
these loci. The DamID technique is an elegant approach to map the
organization of loci relative to nuclear structures [57]. The Chromo-
some Conformation Capture (3C) assay is also powerful, especially in
combination with the use of microarrays [58]. We can be conﬁdent
that the wide-spread use of these techniques in well characterized
cellular systems will greatly enhance our comprehension of the
architecture of methylated loci.
10. Questions for the future
The architecture of the nucleus is a key parameter for the function
of the genome. One of the elements that regulates gene expression is
DNA methylation. How it ties in with the three dimensional
organization of the nucleus is partly understood at best, and many
questions remain. Are methylated loci recruited to a speciﬁc
repressive compartment, or are they pulled away from permissive
regions? Do genes become methylated just because their location, or
their chromatin organization, makes them accessible to methyltrans-
ferases? Conversely, are genes protected against methylation because
they are “in the right place at the right time”? Insulators delimit
euchromatic and heterochromatic regions, and have strong links to
DNA methylation [59]. How do they work in space and time?
The correct pattern of DNA methylation on genes, including those
that are parentally imprinted, is critical for the embryonic develop-
ment of mammals. This pattern undergoes dramatic remodelling steps
in the fertilized egg and in germ cells [60]. How is this connected to
the architecture of chromatin, which is in ﬂux at the same time too
[61]? The expression of MBD proteins, and the distribution of the
methylated chromocenters, are dynamic during development, but do
they only respond to differentiation, or do they actually drive change
by acting on gene expression? The different cells in our bodies have
different epigenomes [62]. Are those dictated by their different
nuclear organizations? A similar question applies to cancer cells, as
opposed to normal ones.
Finally, and most intriguingly, what about DNA demethylation?
This has been shown to occur, at least in cell lines, and the reaction
could be reconstituted in vitro [63]. When and where does this take
place in the nucleus? Fortunately, there is no lack of interesting
questions for the future.
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